Effect of Morus alba on diabetes mellitus type 1
Not Applicable
Completed
- Conditions
- Insulin-dependent diabetes mellitus.Insulin-dependent diabetes mellitus
- Registration Number
- IRCT2015030812438N11
- Lead Sponsor
- Barij Research Center of Medicinal Herbs
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
patients 10 to 30 years who have insulin-dependent diabetes disease and HbA1c in his with more than 7 percent. Exclusion criteria: LDL cholesterol and triglycerides less than 160 and less than 200 respectively. Liver disease, kidney disease, not use of lipid-lowering drugs.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1C. Timepoint: months 0,2,4,6. Method of measurement: percent of glycosylated hemoglobin.;Fasting plasma glucose. Timepoint: months 0,2,4,6. Method of measurement: Enzymatic.;Tg. Timepoint: months 0,2,4,6. Method of measurement: blood sample.;Cholesterol. Timepoint: months 0,2,4,6. Method of measurement: blood sample.;LDL. Timepoint: months 0,2,4,6. Method of measurement: blood sample.;HDL. Timepoint: months 0,2,4,6. Method of measurement: blood sample.;CRP. Timepoint: months 0,2,4,6. Method of measurement: blood sample.;ALT,AST. Timepoint: months 0,2,4,6. Method of measurement: blood sample.
- Secondary Outcome Measures
Name Time Method Taking insulin. Timepoint: months 0,2,4,6. Method of measurement: questionnaire.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Morus alba's glucose-lowering effects in type 1 diabetes?
How does hydroalcoholic Morus alba extract compare to insulin therapy in managing lipid profiles for T1D patients?
Which biomarkers correlate with improved glycemic control in IRCT2015030812438N11 Morus alba trials?
What adverse events are associated with Morus alba supplementation in insulin-dependent diabetes?
Are there synergistic effects of combining Morus alba with GLP-1 agonists in type 1 diabetes treatment?